Dr. Holly Meany (at Children's National Hospital) presents the upcoming SABRE Trial (NCT07172958), a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in participants with relapsed/refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma and Wilms tumor.

Dr. David Loeb (Children's Hospital at Montefiore) makes a repeat guest appearance to present and discuss an upcoming Phase II Clinical Trial centered around DFMO for Ewing sarcoma and Osteosarcoma.

Dr. Maggie Fader (at Nicklaus Children's Hospital) discusses the ongoing Functional Precision Medicine Clinical Trial for relapsed or refractory pediatric cancer patients (NCTNCT05857969). This webinar will outline this team's unique approach to personalized medicine, utilizing patient specific ex vivo Drug sensitivity Testing (DST) and genomic profiling.

Dr. Christine Heske (at NCI) discusses the recently opened PEN-866 (or VTPEN) clinical trial for relapsed and refractory AYA with Ewing or Rhabdomyosarcoma (NCT04890093). We'll discuss the preclinical science behind this trial, key distinguishing features of the newly opened trial, and how patient advocacy and persistence made this trial a reality.

Join us as we head to the other side of the pond, with trial lead Dr. Bernadette Brennan (Royal Manchester Children’s Hospital), to take look at a multi-arm and new clinical trial called INTER-EWING-1 (https://www.bcrt.org.uk/information/clinical-trials/recruiting-clinical-trials/inter-ewing-1).

Dr. Rashmi Chugh (University of Michigan) presents a phase I trial for Ewing sarcoma, centered around a new targeted agent called INBRX-109. INBRX-109 is a recombinant humanized tetravalent antibody targeting human death receptor 5 (DR5). This targeted agent will be given in combination with Irinotecan and Temozolomide.

Dr. Matteo Trucco (Cleveland Clinic) discusses a new upfront trial for Metastatic Ewing sarcoma. METTSEO (Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes) will test the ability to administer frequently changing chemotherapy regimens, based on evolutionary biology principles called sequential second strikes, to patients with widely metastatic Ewing sarcoma in order to stop development of resistance to chemotherapy and improve cure rates.

Dr. David Shulman (Dana Farber Cancer Institute) discusses the newly opened PEEL-224 Phase I/II Clinic Trial (NCT06709495) for relapse or refractory sarcomas in AYAs. PEEL-224 is newly formulated Topoisomerase I Inhibitor with preclinical efficacy as a single agent. For this clinical trial, PEEL-224 will combined with Vincristine and Temozolomide (V, P, T).

Dr. Brian Crompton (at Dana Farber Cancer Institute) discusses the ongoing research behind liquid biopsy detection of Ewing sarcoma cells and ongoing efforts to leverage this technology to risk stratify patients at diagnosis, with the ultimate aim of changing the trajectory of cancer treatment on individual basis.

Join us for this special "trifecta" presentation and discussion on NK cell therapy in pediatric sarcomas. Dr. Dean Lee (Nationwide Children's Hospital) will provide an overview of NK cell therapy, Dr. Bhuvana Setty (Nationwide Children's Hospital) will provide an update on the ongoing TiNKs trial (NCT05634369), and Dr. Wen Luo (New York Medical College) will provide a preview into promising research centered around next generation NK cell therapies (CAR-NK, etc.) for Ewing sarcoma.

In this episode of Ewing’s U, Dr. Chandrika Behura (at Penn State Health Children's Hospital) discusses the research behind a new CK2 inhibitor for solid tumors (including Ewing sarcoma) and shares details about a new clinical trial (BCC021) through the Beat Childhood Cancer Research Consortium.

In this webinar, we'll hear from pediatric radiation oncologist Dr. Matthew Ladra of Children’s National Medical Center (affiliated with Johns Hopkins Sidney Kimmel Cancer Center) on proton radiation and discuss when and how proton radiation therapy might be the best option for local control in Pediatric Sarcomas, with a focus on metastatic disease.

Pediatric oncologist Dr. Filemon Dela Cruz of MSK discusses how cutting-edge Tumor Sequencing and Bionformatics paired with AI modeling can help find druggable master regulators (chokepoints) in Ewing Sarcoma.

Orthooncologist Dr. Thomas Scharschmidt of Nationwide Children's discusses multiple cutting-edge surgical options that are now available to kids with Ewing Sarcoma, with the ultimate aim of using modern technology to improve patient outcomes.